Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
Stallmach A, et al. Among authors: schmelz r.
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7.
Aliment Pharmacol Ther. 2016.
PMID: 27714831
Free article.